Analysts/Institutional Investor Meet/Con. Call Updates

June 25, 2026 To, To, National Stock Exchange of India Limited, BSE Limited, “Exchange Plaza”, Corporate Relationship Department, 5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring, Bandra- Kurla Complex Bandra (East), P.J. Towers, Dalal Street, Mumbai – 400 051 Mumbai – 400 001 NSE Symbol: GLENMARK BSE Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 25/26-27 Our Reference No. 25/26-27 Dear Sir/ Madam, Sub: Intimation of Schedule of Analyst / Institutional Investor Meeting Pursuant to the relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform the details of Analyst / Institutional Investor meeting to be conducted as under: Group / Date Analyst/Institutional Investors/Event Venue Type of Meeting One-on-one June 30, 2026 Investor meetings London Physical Both to July 01, 2026 The company will not be disclosing any Unpublished Price Sensitive Information (UPSI) at these meetings. The schedule of the above-mentioned meetings is subject to change due to exigencies on the part of Investor / Company. We request you to take this intimation on record. Thanking You. For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer ACS - 28839 Glenmark Pharmaceuticals Limited Glenmark House, B. D. Sawant Marg, Andheri (East), Mumbai 400 099, India T: +91 22 4018 9999 F: +91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com